Contents
Download PDF
pdf Download XML
37 Views
15 Downloads
Share this article
Research Article | Volume 31 Issue 11 (November, 2026) | Pages 8 - 13
EARLY OUTCOME OF PATIENTS WITH UNCORRECTED SECONDARY MODERATE TR AFTER LEFT SIDED VALVE SURGERY.
 ,
 ,
 ,
 ,
 ,
1
MBBS, MS, MCH TRAINEE, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
2
MBBS, MS, MCH, DIRECTOR PROFESSOR AND HEAD, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
3
MBBS, MS, MCH, ASSOCIATE PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
4
MBBS, MS, MCH, PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
5
MBBS, MS, MCH, ASSISTANT PROFESSOR, DEPARTMENT OF CARDIO-THORACIC AND VASCULAR SURGERY, SUPER-SPECIALTY BLOCK VMMC AND SAFDARJUNG HOSPITAL, NEW DELHI.
Under a Creative Commons license
Open Access
Received
Oct. 3, 2026
Revised
Oct. 28, 2026
Accepted
Nov. 5, 2026
Published
Nov. 19, 2026
Abstract

Moderate tricuspid regurgitation (TR) management remains controversial. This study evaluated outcomes of conservative management in patients with moderate TR and tricuspid index (TI) <21. Methods: This single-centre retrospective observational study included 66 patients who underwent left-sided valve surgery between April 2018 and December 2025 without concomitant tricuspid valve intervention. Patients with secondary moderate tricuspid regurgitation and a tricuspid annular index <21 were followed clinically and echocardiographically for 12 months. Results: The cohort included 66 patients (mean age, 40.7 ± 12.1 years), comprising 50 MVR (75.8%) and 16 DVR (24.2%) patients. Preoperatively, 33 patients (50%) had atrial fibrillation (AF), with no concomitant ablation. At 12 months, TR regressed to mild in 55 patients (83.3%), while 11 (16.7%) demonstrated non-regression, including 10 with persistent moderate TR and 1 with progression to severe TR. NYHA class II was observed in 60 patients (90.9%), while 6 (9.1%) remained in class III. RVSP showed early postoperative stabilization, maintained throughout follow-up. Conclusion: Non-operative management of moderate TR with TI <21 appears safe during short-term follow-up.

INTRODUCTION

Clinically significant tricuspid regurgitation (TR) affects more than 70 million people worldwide [1], with women experiencing a 4.3-fold higher prevalence than men [2].

 

Historically, the medical community underemphasized the clinical significance of tricuspid valve function relative to the mitral and aortic valves, assuming that severe TR could be adequately managed with medical therapy alone [3]. However, modern paradigms have shifted significantly. Left uncorrected during left-sided valve surgery, mild-to-moderate functional TR can progress in more than 25% of patients [4]. This progression drives right-sided heart failure, recurrent hospitalizations, and decreased long-term survival, independent of left ventricular ejection fraction (LVEF), RV dimensions, or pulmonary artery pressures [5,6,7].

 

The institution policy has been to intervene in all patients having moderate TR undergoing left sided valve surgery having annular dilatation ( >40 mm or 21 mm/cm2 ) [8]. This Institutional policy was based on the prevailing international guidelines and resources available in the institution.

 

The patients who did not undergo concomitant tricuspid valve repair with left sided valve intervention based on the above policy were included in this study. The purpose of this study was to evaluate the clinical and echocardiographic outcomes of these patients.

MATERIALS AND METHODS

Patient Selection

We conducted a retrospective analysis of 66 patients who underwent left sided valve surgery between April 2018 and December 2025. Those who did not undergo Tricuspid valve intervention and had secondary moderate TR with indexed tricuspid annular diameter (TAI) < 21 were included in the study.

Patients who had primary Tricuspid regurgitation and patients undergoing additional procedures like concomitant coronary artery bypass grafting (CABG) were excluded.

Clinical and surgical details were retrieved from institutional databases, intraoperative logs, and subsequent outpatient department (OPD) follow-up records. Functional capacity was assessed using the New York Heart Association (NYHA) functional classification via structured patient interviews.

 

Echocardiographic Evaluation

Transthoracic echocardiography (TTE) was routinely performed preoperatively and at 3, 6, and 12 months postoperatively as per institutional protocol. Key parameters recorded included LVEF, right ventricular systolic pressure (RVSP), and TR severity grade (mild, moderate, or severe). TR severity was quantified semi quantitatively using colour flow mapping (CFM) from the standard apical four-chamber view. The tricuspid annular index was calculated as follows:

TAI = Tricuspid Annular Diameter (mm)/Body Surface Area (m2)

 

Statistical Analysis

Continuous variables are expressed as mean ± standard deviation (SD), and categorical variables are presented as frequencies and percentages. To account for repeated measures within individual subjects over time, TR severity was dichotomized into "mild" versus “moderate". Temporal changes in TR severity across the 3-, 6-, and 12-month intervals were analysed using Cochran’s Q test and p value < 0.05 was considered statistically significant.

 

RESULTS

Baseline Characteristics

The final cohort comprised 66 patients with a mean age of 40.7 ± 12.1 years [range 19-68 years]. Mitral valve replacement (MVR) was performed in 50 patients (75.8%) and double valve replacement (DVR) was done in 16 patients (24.2%). Preoperative rhythm analysis revealed an equal distribution in sinus rhythm (n=33) and atrial fibrillation (AF) (n=33). No patient underwent a concomitant ablation procedure.

 

Postoperative Evolution of Tricuspid Regurgitation

During the study period significant spontaneous regression of TR was observed early and maintained throughout the study period:

  • At 3 Months: A total of 54 patients (81.8%) demonstrated regression to mild TR, 12 patients (18.2%) continued to have moderate TR, and none of the patients progressed to severe TR.
  • At 6 Months: A total of 55 patients (83.3%) exhibited mild TR, 10 patients (15.2%) remained with moderate TR, and 1 patient (1.5%) progressed to severe TR.
  • At 12 Months: The distribution remained same as the 6-month interval status.

 

Based on the 12-month outcome, two phenotypes were identified: TR regression and TR non regression.

TR regression occurred in 55 patients (83.3%) and TR non regression in 11 patients (16.7%). Of this one patient (1.5%) progressed to severe TR, while 10 patients continued to have moderate TR. [Fig 1]

After 12 months, 60 patients (90.9%) were classified as NYHA functional class II and 6 patients (9.1%) as class III. Echocardiographic assessment showed early postoperative stabilization of RVSP that persisted through the 12-month assessment.

Fig 1: Evolution in severity of Tricuspid Regurgitation over a period of 1 year.

Predictors of TR non regression 

The established risk factors like Atrial Fibrillation, Age, Mean Annular Diameter and pulmonary artery pressures were not found to be independent risk factors of TR non regression on univariate analysis.[Table 1, Figure 2 ]

Table -1: Risk factors for non-regression of TR

Fig 2: Univariate odds ratios for TR regression.

DISCUSSION

For decades, secondary tricuspid regurgitation was considered a passive bystander in left-sided valvular disease, with clinicians anticipating uniform regression following the correction of mitral or aortic lesions [8]. However, contemporary data established that prognostic impact of uncorrected TR, which frequently causes progressive right-sided heart failure and excess mortality [9-11].

 

Nath et al. demonstrated that moderate-to-severe TR is independently linked to worse mid- and long-term survival compared to mild TR [12].

 

The 2020 AHA/ACC guidelines on management of patients with valvular heart disease advocate intervention in patients with secondary mild or moderate TR with annular dilatation or having signs of right heart failure [13].

The 2021 ESC/EACTS guidelines on management of patients with valvular heart disease advocate tricuspid intervention in patients with secondary mild or moderate TR with annular dilatation [11].

 

Our institutional policy was however to intervene in patients with only moderate TR with annular dilatation. The patients having mild TR or moderate TR without annular dilatation did not undergo tricuspid intervention.

 

Kwak et al evaluated the development of late de novo TR in 335 patients who underwent left-sided valve surgery between 1992 and 1995 with no significant preoperative TR and who completed at least 5 years of Echo follow-up. The study subjects were evaluated over a mean follow-up duration of 11.6 ± 2.1 years. Results indicated that significant late TR developed in 90 patients, representing 26.9% of the cohort. Although univariate analysis showed that late TR was associated with older age, greater left atrial dimension, prior valve surgery, and having undergone mitral valve surgery, multivariate analysis identified preoperative atrial fibrillation as the sole independent predictor of late TR development, carrying an odds ratio of 5.37. Furthermore, patients who developed significant late TR experienced a significantly lower event-free survival rate than those who did not. Our study did not look at this subset of patients [4].

 

Song et al evaluated the incidence and clinical impact of late significant TR in 638 patients who underwent successful left-sided valve surgery without any concomitant tricuspid repair. Patients included in the study had mild preoperative TR. The mean echocardiographic follow-up of 64 ± 30 months and a mean clinical follow-up of 101 ± 24 months. Results demonstrated an overall incidence of late significant TR of 7.7%. Multivariate analysis revealed that older age, female gender, rheumatic etiology, atrial fibrillation, and the peak pressure gradient of TR at follow-up were independent risk factors for developing late significant TR. Furthermore, the development of late significant TR was associated with adverse clinical outcomes, as these patients exhibited a significantly lower 8-year clinical event-free survival rates. Our study however looked at patients with moderate TR having no annular dilatation [14].

 

Bolumburu et al. did prospective observational study investigated the progression of TR in a cohort of 1,442 patients presenting with at least moderate TR at baseline. Over a median echocardiographic follow-up duration of 2.3 years, 19% of patients experienced TR progression, 43% remained stable, and 38% exhibited TR regression. The results indicated that older age, lower body mass index, chronic kidney disease, worse NYHA functional class, and right ventricular dilation were independent predictors of TR progression. Furthermore, TR progression correlated with increased chamber dilation, reduced left ventricular ejection fraction, and significantly higher rates of cardiovascular mortality and heart failure hospitalizations. Our study on the contrary found that significant number of patients (83.1%) patient had regression of TR and only 1.5% patients had progression of TR at 1 year follow up. None of the risk factors we investigated were found to be predictors of TR non regression [15].

 

Kim et al. demonstrated that combining a surgical ablation procedure with left-sided valve operations can significantly mitigate late TR progression by restoring sinus rhythm [16]. However we did not perform any ablation procedure in our cohort.

 

The 2025 ESC/EACTS guidelines for management of patients with valvular heart disease advocate tricuspid valve intervention in all patients having moderate secondary TR undergoing left sided valve surgery, however our study supports a more conservative approach.

 

Study Limitations

This study has several limitations that restrict the generalizability of its findings:

  • Sample Size and Follow-Up: The study is limited by a small sample size ($N=66$) and a short follow-up window (12 months).
  • Echocardiographic Metrics: Detailed volumetric and functional indices for the right ventricle (e.g., TAPSE, RV fractional area change) were not available.
  • Hemodynamic Variability: Semiquantitative CFM metrics used to grade TR remain highly sensitive to fluctuations in perioperative cardiac output, preload, and afterload.
CONCLUSION

An evidence-based approach to treating moderate functional tricuspid regurgitation during left-sided valve surgery is prudent and should be followed. Conservative management is highly effective and reliable when guided by a tricuspid annular index < 21. Utilizing the TAI as a definitive surgical filter helps prevent unnecessary tricuspid interventions while maintaining excellent short-term clinical safety and promoting spontaneous valvular regression.

REFERENCES
  1. Kolte D, Elmaria S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020;10(1):89-97.
  2. Badano L, Muraru D, Enriquez-Sarano M. Assessment of functional tricuspid regurgitation. Eur Heart J. 2013;34(25):1875-1885.
  3. Rizzoli G, Vendramin I, Nesseris G, Bottio T, Cuglielmi C, Schiavon L. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg. 2004;77(5):1607-1614.
  4. Kwak JJ, Kim YJ, Kim MK, et al. Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with long-term echocardiographic examinations. Am Heart J. 2008;155(4):732-737.
  5. Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21(2):157-165.
  6. Ambrosino M, Sangoi M, Monzer N, Irving B, Fiorilli P, Khazan B, et al. Tricuspid regurgitation: a review of current interventional management. J Am Heart Assoc. 2024;13(6):e032999.
  7. Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. 2005;80(3):845-850.
  8. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg. 2011;141:1431-1439.
  9. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol. 2015;65:1931-1938.
  10. Badhwar V, Rankin JS, He M, Jacobs JP, Furnary AP, Fazzalari FL, et al. Performing concomitant tricuspid valve repair at the time of mitral valve operations is not associated with increased operative mortality. Ann Thorac Surg. 2017;103:587-593.
  11. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, et al. Outcomes of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. Ann Thorac Surg. 2020;109:1227-1232.
  12. Nath J, Foster E, Heidenreich P. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43(3):405-409.
  13. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg. 2005;79(1):127-132.
  14. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, Kang DH, Lee JW, Song JK. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart. 2009 Jun;95(11):931-6.
  15. Arteagoitia Bolumburu A, Monteagudo Ruiz JM, Mahia P, Pérez David E, González T, Sitges M, et al. Determinants of tricuspid regurgitation progression and its implications for adequate management. JACC Cardiovasc Imaging. 2024;17(6):579-591.
  16. Kim HK, Kim YJ, Kim KI, et al. Impact of the Maze operation combined with left-sided valve surgery on the change in tricuspid regurgitation over time. Circulation. 2005;112(9 Suppl):I14-I19
Recommended Articles
Chat on WhatsApp
© Copyright Journal of Heart Valve Disease